
Claims

1. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis in a patient in need thereof, ~~wherein the compound in the medicament is to be administered at a daily amount ranging from about 20 mg to about 300 mg or a pharmaceutically acceptable salt thereof,~~ wherein Formula I is represented by:



and wherein the patient is orally administered a compound of Formula I at a daily amount ranging from 75 mg to 100 mg or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I or a pharmaceutically acceptable salt thereof is administered twice per day, and wherein

   (i) the patient has consumed food within 1 hour prior to receiving said compound;
   (ii) the administering is performed at a time the patient consumes a meal; or
   (iii) the patient consumes a meal within 1 hour after receiving said compound.

~~2. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount ranging from about 25 mg to about 150 mg or a pharmaceutically acceptable salt thereof.~~

2. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount ranging from 85 mg to 95 mg or a pharmaceutically acceptable salt thereof.

3. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount of about 90 mg or a pharmaceutically acceptable salt thereof.

4. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount of 90 mg or a pharmaceutically acceptable salt thereof.

~~4. The use of any one of claims 1-3, wherein the medicament is to be administered only once per day.~~

~~5. The use of any one of claims 1-4, wherein the medicament is to be administered twice per day.~~

5.~~6.~~ The use of claim 1, wherein the medicament is to be orally administered twice per day as a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of about 45 mg or a pharmaceutically acceptable salt thereof.

6. The use of claim 1, wherein the medicament is to be orally administered twice per day as a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of 45 mg or a pharmaceutically acceptable salt thereof.

~~7. The use of any one of claims 1-6, wherein the patient has recently consumed food prior to receiving the medicament.~~

~~8. The use of any one of claims 1-6, wherein the patient has consumed food within 1 hour prior to receiving the medicament.~~

~~9. The use of any one of claims 1-6, wherein the patient has not recently consumed food prior to receiving the medicament.~~


~~10. The use of any one of claims 1-6, wherein the patient has not consumed food within 1 hour prior to receiving the medicament.~~

~~11. The use of any one of claims 1-6, wherein the patient consumes a meal within 1 hour of receiving the medicament.~~

~~12. The use of any one of claims 1-6, wherein the medicament is to be administering at a time when the patient consumes a meal.~~

7.~~13.~~ Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis, wherein the medicament is to be orally administered to a patient in need thereof two times per day as a unit dosage containing the compound in

an amount ranging from ~~about~~ 25 mg to ~~about~~ 50 mg or a pharmaceutically acceptable salt thereof, wherein Formula I is represented by:



and wherein

(i) the patient has consumed food within 2 hours prior to receiving the unit dosage;

(ii) said administering is performed at the time the patient consumes a meal; or

(iii) the patient consumes food within 30 minutes after receiving the unit dosage.

8.~~14.~~ The use of claim 7~~13~~, wherein the unit dosage is to be administered to the patient in the form of two unit formulations containing compound of Formula I or a pharmaceutically acceptable salt thereof.

9.~~15.~~ The use of claim 7~~13~~, wherein the unit dosage is to be administered to the patient in the form of a single unit formulation containing compound of Formula I or a pharmaceutically acceptable salt thereof.

10.~~16.~~ The use of any one of claims 7-9~~13-15~~, wherein the unit formulation(s) are in the form of a tablet or capsule.

11.~~17.~~ The use of any one of claims 7-10~~13-16~~, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.


12.~~18.~~ The use of any one of claims 7-11~~13-17~~, wherein a first unit dosage is to be administered to the patient in the morning, and a second unit dosage is to be administered to the patient in the evening.

~~19. The use of any one of claims 13-18, wherein the patient has consumed food within 2 hours prior to receiving the unit dosage.~~

13.~~20.~~ The use of any one of claims 7-12~~13-18~~, wherein the patient has consumed food within 1 hour prior to receiving the unit dosage.

~~21. The use of any one of claims 13-18, wherein the patient consumes food within 30 minutes of receiving the unit dosage.~~

14.~~22.~~ Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis, wherein the medicament is to be orally administered to a patient in need thereof twice daily as a unit dosage containing the compound in an amount of about 45 mg or a pharmaceutically acceptable salt thereof, wherein the patient consumes a meal within ~~about~~ 1 hour ~~of~~ after the administration, and Formula I is represented by:



15.~~23.~~ The use of claim 14~~22~~, wherein the unit dosage is to be administered to the patient in the form of one or more unit formulations containing the compound of Formula I or a pharmaceutically acceptable salt thereof.

16.~~24.~~ The use of claim 15~~23~~, wherein the unit formulation(s) are in the form of a tablet or capsule.

17. The use of any one of claims 14-16, wherein the unit dosage contains about 45 mg of compound of Formula I.

18. The use of any one of claims 14-16, wherein the unit dosage contains 45 mg of compound of Formula I.

19.~~25.~~ The use of any one of claims 14-18~~22-24~~, wherein the medicament is to be administered at the time the patient consumes a meal.

20.~~26.~~ The use of any one of claims 14-19~~22-25~~, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.

21.~~27.~~ The compound for use of any one of claims 14-20~~22-26~~, wherein a first unit dosage is administered to the patient in the morning, and a second unit dosage is administered to the patient in the evening.

22.~~28.~~ The compound for use of any one of claims 14-18~~22-24~~, wherein a first unit dosage is administered to the patient at the time the patient consumes a breakfast meal in the morning, and a second unit dosage is administered to the patient at the time the patient consumes a dinner meal in the evening.

23. The compound for use of any one of claims 14-22, wherein the patient receives the unit dosage two times per day for a duration of at least 2 weeks.

24. The compound for use of any one of claims 14-22, wherein the patient receives the unit dosage two times per day for a duration of at least 1 month.

25. The compound for use of any one of claims 14-22, wherein the patient receives the unit dosage two times per day for a duration of at least 6 months.

26.~~29.~~ The compound for use of any one of claims 1-17~~1-28~~, wherein the multiple sclerosis is relapsing multiple sclerosis, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, or progressive-relapsing multiple sclerosis.

27.~~30.~~ The compound for use of any one of claims 1-26~~1-28~~, wherein the multiple sclerosis is relapsing multiple sclerosis.

28. The compound for use of any one of claims 1-27, wherein the patient is an adult human.

29. The compound for use of any one of claims 1-28, wherein the patient is in a fed state when the compound of Formula I or pharmaceutically acceptable salt thereof is administered to the patient.